

NUTRACEUTICAL FUNCTIONS OF GREEN TEA

Bonomo, Maria Grazia^{1,7}; Catalano, Alessia²; Finelli, Francesca^{3,*}; Giuzio, Federica⁴; Iacopetta, Domenico⁵; Ceramella, Jessica⁵; Sinicropi, Maria Stefania⁵; Capasso, Anna⁶; Saturnino, Carmela¹

¹University of Basilicata, Department of Science, Viale dell'Ateneo Lucano n. 10, 85100 Potenza, Italy

²University of Bari "Aldo Moro", Department of Pharmacy-Drug Sciences, Via Orabona n. 4, 70126 Bari, Italy

³Struttura Complessa UOP-AO "G. Moscati" Avellino, Italy

⁴International PhD Programme 'Sciences', University of Basilicata, Department of Science, Viale dell'Ateneo Lucano n. 10, 85100 Potenza, Italy

⁵University of Calabria, Department of Pharmacy, Health and Nutritional Sciences, 87036 Arcavacata di Rende, Italy

⁶University of Salerno, Department of Pharmacy, Via Giovanni Paolo II n. 132, 84084 Fisciano (SA), Italy

⁷Spinoff TNcKILLERS, Viale Dell'Ateneo Lucano 10, 85100 Potenza, Italy

[*medfinelli@gmail.com](mailto:medfinelli@gmail.com)

Abstract

Today, the diffusion of neoplastic diseases is a widespread phenomenon. Thus, it is always necessary to identify new molecules able to fight them. In this paper, we will deal with the interesting antineoplastic properties of green tea. We will describe the different and plausible anticancer mechanisms of epigallocatechin gallate (EGCG), the major polyphenol found in green tea, and in particular the biochemical and computational discovery of a new target for the treatment of this disease will be discussed. The bio-active substances present in tea are essentially represented by methylxanthines, as well as by the antioxidant phenolic fraction (flavonoids). Among the other active substances contained in lower concentrations there are vitamins (B, C and K), amino acids (L-theanine) and minerals (aluminium and manganese). Tea extracts, particularly EGCG, could represent the starting point for the potential emergence of new drugs for the treatment of neoplastic diseases. Other activities of tea, as the involvement in neurodegenerative diseases prevention, as well as the antioxidant, antibacterial, antifungal and antiviral effects, will be also briefly described.

Keywords: tea, epigallocatechin gallate (EGCG), tumor, flavonoids, green tea catechins (GTCs), nutraceuticals.

Introduction

Tea is the most consumed drink in the world after water. Green tea is a non-fermented tea that contains numerous components endowed with antioxidant activity, including phenols (especially catechins) [1]. Phenols constitute an important class of secondary metabolites mainly widespread in the plant kingdom. They are responsible for many organoleptic characteristics appearing both as precursors of aromas and colours, and for their nutritional characteristics [2,3]. Tannins are phenols known for their activity as astringents, anthocyanins for the colours of the flowers, phenolic acids for the acidic taste, and some flavonoids for the bitter taste. The total phenolic compounds can reach 35% of the composition of the dry tea leaves. Fermentation modifies the qualitative and quantitative composition of the tea phenols giving rise to complex polyphenols represented by aromatic and coloured compounds such as tea flavins and tea rubigo (flavonols) present mainly in black tea. In green and yellow teas, oxidation is deliberately blocked by inhibiting the action of oxidase. Therefore, during the growth of the leaves on the plant, the content of polyphenols decreases quantitatively and qualitatively: thus, the best quality of tea is obtained from young leaves [4]. Phenols are responsible for the numerous beneficial activities of green tea. Polyphenols are proposed to function via various mechanisms, the most important of which is related to reactive oxygen species (ROS) [5,6]. Moreover, noticeable melatonin contents were found in green tea [7-9]. The bioactive components of green tea, especially polyphenols, showed antioxidant capacity and inhibitory effects against digestive enzymes that will be briefly described in this paper.

Flavonoids

Flavonoids are among the most abundant phenolic compounds present in green tea [10-14]. Their structure consists of a diphenylpropane skeleton, *i.e.* two benzene rings connected by a closed pyranic ring. The innumerable structural characteristics of the ring and the glycosylation and dihydroxylation patterns of the three rings, make

the flavonoids the largest group of natural molecules with multiple biological activities, such as antioxidant, anti-inflammatory, antihypertensive and antiviral [15-20]. Flavonoids can be classified into several classes: flavones, flavonols, flavanones, flavanonols, flavanols or catechins and anthocyanins [21]. They have been recently studied for new pharmaceutical preparations, such as nanoformulations and incorporation into liposomes, in order to improve their bioavailability [22-28]. Among them, our attention was focused on flavanols (catechins), which are a sub group of flavonoids and represent about 20-30% of the total weight. The main catechins in tea, named green tea catechins (GTCs) are: epigallocatechin-3-gallate (EGCG), mainly responsible for the beneficial effects of tea, epigallocatechin (EGC), epicatechin-3-gallate (ECG) and epicatechin (EC) (Figures 1-4).

EGCG

The benefits of green tea correspond for the most part to the benefits of the catechins it contains, namely EGCG. The main activity of EGCG is to enhance the antioxidant defences and therefore decrease cell damage, producing healthy effects on all tissues. Green tea has 10 times higher EGCG content than black tea (about 180 mg per cup of green tea) and 2.5 times higher than oolong tea. EGCG is among the most studied and most abundant catechins in tea, accounting for 50-80% of the total catechin content [29,30]. The nutritional health properties of EGCG may be related to its structure, with three aromatic rings linked together by a pyranic ring. The antioxidant activity of EGCG results from the transfer reactions of a hydrogen atom or a single electron, involving the hydroxyl groups of the rings [31]. The onset and progression of cancer are linked to epigenetic alterations including aberrant methylation and acetylation of DNA. EGCG is, therefore, a molecule capable of inhibiting tumors, particularly of the lung, oral-digestive tract, and prostate. An association between green tea consumption and reduced risk of stomach cancer was demonstrated in Japan [32]. One of the most promising studies in prostate cancer was performed by Bettuzzi et al. [33], who demonstrated that GTCs are safe and very effective for treating premalignant lesions before prostate cancer develops. Two hundred individuals with high-

grade prostatic intraepithelial neoplasia received 600 mg of GTCs or placebo for 12 months. EGCG in mice was shown to inhibit lung carcinogenesis induced by a specific nitrosamine of tobacco, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, by inhibiting the formation of 8 hydroxy-deoxyguanosine [34]. Moreover, daily consumption of green tea, and diets rich in natural polyphenols have been linked to a reduced risk of inflammatory bowel disease (IBD) [35,36].

EGCG activities

Inhibition of angiogenesis

Tumor growth is closely related to angiogenesis, which supplies oxygen and nutrients to cancer cells [37,38]. Vascular endothelial growth factor (VEGF) has been recognized as one of the main angiogenic factors. EGCG was shown to inhibit angiogenesis and tumor growth, by down-regulating VEGF expression in HT29 human colon cancer cells, cultured in the absence of serum and *in vivo*, as well as in human breast cancer and pancreatic cancer cells [10,39]. In addition to this activity, EGCG also modulates the activity of epidermal growth factor receptor (EGFR) and platelet growth factor receptor (PDGFR), tyrosine kinase proteins implicated as contributing factors in the proliferation of cells. The mechanisms responsible for modulation of the EGFR signal are different: the inhibition of EGFR autophosphorylation [40]; the increase in EGFR phosphorylation on Ser1046/1047 by the mitogen-activated protein kinase p38 (MAPK) in colon cancer, resulting in down-regulation of EGFR expression [41]; the induction of the internalization of EGFR in the endosome [42]; the modulation of membrane lipid organization, and therefore the inhibition of binding of EGF to EGFR [43]. Furthermore, EGCG also inhibits PDGFR phosphorylation, its downstream signalling in smooth muscle cells and spheroidal formation of human glioblastoma cells [44].

Inhibition of tumor migration

The inhibition of migration and invasion of tumor cells could also be a target of antineoplastic

therapy. EGCG downregulates hepatocyte growth factor (HGF)-induced matrix metalloproteinases, particularly MMP-9 and determines the activation of urokinase-type plasminogen activator (uPA) capable of inhibiting invasion and metastasis in hypopharyngeal carcinoma cells [45].

Induction of cell death

Apoptosis is a key strategy that is responsible for deletion of cells in normal tissues; it also occurs in specific pathologic contexts. The relationship between antiapoptotic (Bcl-2 and Bcl-xL) and proapoptotic (Bax and Bak) factors of the Bcl-2 family, decides cell susceptibility against anti-drugs tumors in cancer cells. Furthermore, apoptotic proteins with only one BH domain (BH3-only including PUMA, Noxa, and Bim) bind with Anti-Bcl-2 proteins to inhibit their functions, resulting in the induction of apoptosis. Several studies have reported that EGCG modulates the expression of the Bcl-2 family of proteins: it induces apoptosis by down-regulation of Bcl-2 and/or up-regulation of Bax expression in nasopharyngeal carcinoma cells, breast, prostate, bladder and ovarian. On the other hand, the induction of PUMA by EGCG also leads to apoptosis in colon cancer cells. The modulation of the expression of the Bcl-2 family of proteins by EGCG is one of the important factors for the induction of cell death by apoptosis: in this case, the tumor suppressor gene p53 plays a critical role in the inhibition of carcinogenesis through cell cycle regulation, apoptosis and DNA repair. Therefore, p53-mediated signalling is involved in anticancer drug apoptosis. EGCG may be able to induce p53-mediated cell death by inducing the activity and stabilization of this molecule. In prostate and breast cancer cells, EGCG increases the expression of Bax, a downstream target of p53 [46,47].

EGCG targets

Inhibition of kinases

In recent years, multi-target kinase inhibitors have become a focal point of interest for physicians, pharmacists and medicinal chemistry researchers. Some of them have been recently approved in antineoplastic therapy [48-50]. Therefore, the broad inhibition of multiple targets, rather than a single

specific target, could represent a more comprehensive strategy for the treatment of malignancies and other diseases [51-57]. Studies *in vitro* demonstrated that EGCG was able to inhibit the proliferative mechanism of some tyrosine kinases (RTKs) including EGFR, IGF-1REVEGFR, by inhibiting the phosphorylation of these receptors. The block of MAPK and PI3K signalling pathways results in the downstream inactivation of the transcription factors AP-1 and NfKB, whose cell proliferative activity is unregulated in subjects affected by neoplasia. The anticarcinogenic activity of EGCG has in fact been confirmed recently thanks to the computational discovery of a new target: it is a serine-threonine kinase (RSK2), another factor implicated in cell proliferation [58]. The computational screening of the molecules able to bind it specifically, only anticipated what was then identified *in vitro*: EGCG binds the RSK kinase on both N and T terminal catalytic domains, preventing phosphorylation and therefore the activation of both the protein, same as its substrate; all this, therefore, leads us to reflect on a better activity of catechin towards multiple targets.

Inhibition of histone H3 phosphorylation

The 90 kDa ribosomal S6 kinase-2 (RSK2) is a growth factor-stimulated protein kinase. It translocates to the nucleus when activated by growth factors, peptide hormones, or neurotransmitters: once in the nucleus, RSK2 can phosphorylate various nuclear proteins, including several histones, thus mediating numerous cellular processes [59]. One of its known phosphorylation substrates is histone H3 [60,61]. EGCG was shown to influence the ability of RSK2 to phosphorylate histone H3 through a kinase immune-precipitation assay. The complete structure of RSK2 was transfected into 293 cells and subsequently the RSK2 proteins were immune precipitated with specific antibodies. The precipitates were directly subjected to an *in vitro* kinase test with histone H3 (1µg) as substrate. The following treatment with EGCG resulted in a dose-dependent inhibition of Ser10 phosphorylation of histone H3 [58]. Based on its broad substrate specificity, the RSK2 protein could mediate a variety of cellular processes, such as cellular proliferation and transformation. RSK2 was demonstrated to play an important role in cell

transformation induced by tumor promoters such as EGF and TPA [62]. Overall, these results indicate that EGCG is a novel natural compound that effectively inhibits RSK2 activity. Furthermore, the results showed that EGCG has a high similarity to two known RSK2 inhibitors, quercitrin [63] and afzelin [64], a further valid element for a better understanding of the chemopreventive activity of this molecule.

Antibacterial, antifungal and antiviral effects of green tea

Over the past two decades, several studies have reported that EGCG has anti-infective properties. Its antiviral activity has been demonstrated towards several families of viruses, such as Retroviridae, Orthomyxoviridae and Flaviviridae which include important human pathogens such as virus (HIV), influenza A virus and hepatitis C virus [65]. Furthermore, EGCG seems to interfere with the DNA replication cycle of viruses such as that of hepatitis B, the herpes simplex virus and adenovirus [66]. The use of green tea is used for the treatment of oral potentially malignant disorders (OPMDs), such as lichen planus [67], along with pharmacological therapies, such as thalidomide [68]. Recently, its potential application in coronavirus disease 2019 (COVID-19) has been proposed [69,70]. However, even if the molecular effects of EGCG have not been fully understood yet, there are results that indicate that it binds to lipid membranes and affects the folic acid metabolism of bacteria and fungi by inhibiting the cytoplasmic dihydrofoloreductase enzyme: this mechanism would explain the antibacterial, antifungal and antiviral effects of EGCG [71]. EGCG was recently shown to act against biofilms, ubiquitous multicellular aggregates of bacteria or fungi generally refractory to antibiotic treatment [72]. Biofilm formation was demonstrated to be impaired by EGCG for many more bacteria, also difficult to eradicate, such as *Enterococcus faecalis* [73,74] and *Candida* spp. [75].

Effect of green tea in neurodegenerative diseases and antioxidant activity

Green tea prevents neurodegenerative diseases. *In vitro* studies demonstrate the protective effects

of GTCs in neurodegenerative diseases: some neuroprotective studies have shown that both green tea extract and EGCG have very potent activity in preventing striatal dopamine (DA) depletion and grey matter in the central nervous system loss in dopaminergic neurons of mice. Furthermore, the same researchers reported EGCG ability to chelate iron. This finding gives further hope for its neuroprotective effect as iron accumulates in neurons and microglia of the nervous system of patients with Parkinson's [76]. Green tea has been recently shown to reduce oxidative stress in part by its ability to bind free iron, a micronutrient that is both essential for and toxic to all living organisms. Green tea may act to increase the lifespan of the fruitfly *Drosophila melanogaster* in part by the regulation of iron regulators, specifically, *mitoferrin*, a mitochondrial iron transporter, and reduction of mitochondrial iron [77-79].

Conclusions

The habitual consumption of tea could be an effective method for the prevention of certain diseases over time. The study of the effects of tea at the molecular level, leading to the isolation of active substances, seems to improve the conditions of several diseases. However, it is too early to state with certainty the therapeutic activity of green tea extracts in the treatment of the diseases. Surely, *in vitro* studies have shown that EGCG, the main polyphenolic component of green tea, is an efficient substance for various molecular targets. Unlike specific inhibitors of single targets, EGCG is as an inhibitor of multiple signalling pathways. It might be able to reduce drug resistance by hindering the activation of alternative signalling pathways, thus representing the first step towards the introduction of a new drug, able to act against many and important diseases such as cancer.

References

1. Cabrera, C., Artacho, R., Giménez, R. (2006). Beneficial effects of green tea—a review. *Journal of the American College of Nutrition*, 25(2), 79-99.
2. Crozier, A., Jaganath, I. B., Clifford, M. N. Phenols, polyphenols and tannins: An overview. In *Plant Secondary Metabolites: Occurrence, Structure and Role in the Human Diet*; Crozier, A., Clifford, M., Ashihara, H., Eds.; Blackwell: Oxford, UK, 2006; pp. 1-24.
3. Catalano, A., Carocci, A., Fracchiolla, G., Franchini, C., Lentini, G., Tortorella, V., et al. (2004). Stereospecific synthesis of “*para*-hydroxymexiletine” and sodium channel blocking activity evaluation. *Chirality*, 16(2), 72-78.
4. Guo, X. Y., Lv, Y. Q., Ye, Y., Liu, Z. Y., Zheng, X. Q., Lu, J. L., et al. (2021). Polyphenol oxidase dominates the conversions of flavonol glycosides in tea leaves. *Food Chemistry*, 339, 128088.
5. Ohishi, T., Fukutomi, R., Shoji, Y., Goto, S., Isemura, M. (2021). The beneficial effects of principal polyphenols from green tea, coffee, wine, and curry on obesity. *Molecules*, 26(2), 453.
6. Iacopetta, D., Mariconda, A., Satumino, C., Caruso, A., Palma, G., Ceramella, J., et al. (2017). Novel gold and silver carbene complexes exert antitumor effects triggering the reactive oxygen species dependent intrinsic apoptotic pathway. *ChemMedChem*, 12(24), 2054-2065.
7. Herrera, T., Aguilera, Y., Rebollo-Hernandez, M., Bravo, E., Benítez, V., Martínez-Sáez, N., et al. (2018). Teas and herbal infusions as sources of melatonin and other bioactive non-nutrient components. *LWT*, 89, 65-73.
8. Carocci, A., Catalano, A., Lovece, A., Lentini, G., Duranti, A., Lucini, V., et al. (2010). Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. *Bioorganic & Medicinal Chemistry*, 18(17), 6496-6511.
9. Carocci, A., Catalano, A., Bruno, C., Lovece, A., Roselli, M. G., Cavalluzzi, M. M., et al. (2013). N-(Phenoxyalkyl) amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca²⁺/CaM-dependent kinase II. *Bioorganic & Medicinal Chemistry*, 21(4), 847-851.
10. Pesca, M. S., Dal Piaz, F., Sanogo, R., Vassallo, A., Bruzual de Abreu, M., Rapisarda, A., et al. (2013). Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities. *Journal of Natural Products*, 76(1), 29-35.
11. Gualtieri, M. J., Malafrente, N., Vassallo, A., Braca, A., Cotugno, R., Vasaturo, M., et al. (2014). Bioactive limonoids from the leaves of *Azadirachta indica* (Neem). *Journal of Natural Products*, 77(3), 596-602.

12. Aversano, R., Contaldi, F., Adelfi, M. G., D'Amelia, V., Diretto, G., De Tommasi, N., et al. (2017). Comparative metabolite and genome analysis of tuber-bearing potato species. *Phytochemistry*, 137, 42-51.
13. Malafronte, N., Vassallo, A., Dal Piaz, F., Bader, A., Braca, A., De Tommasi, N. (2012). Biflavonoids from *Daphne linearifolia* Hart. *Phytochemistry Letters*, 5(3), 621-625.
14. Mariconda, A., Vassallo, A., Bonomo, M. G., Calabrone, L., Salzano, G., Claps, M., Sinicropi, M. S., Capasso, A., Satumino, C. (2020). Herbal Formulations of *Thymus Serpyllum* L. and *Hypericum Perforatum* L. from Southern Italy: preparation and chemical characterization. *Pharmacologyonline*, 1, 1-10).
15. Santarsiero, A., Convertini, P., Vassallo, A., Santoro, V., Todisco, S., Iacobazzi, D., et al. (2021). Phenolic Compounds of Red Wine Aglianico del Vulture Modulate the Functional Activity of Macrophages via Inhibition of NF- κ B and the Citrate Pathway. *Oxidative Medicine and Cellular Longevity*, 2021.
16. Tebboub, O., Cotugno, R., Oke-Altuntas, F., Bouheroum, M., Demirtas, Í., D'Ambola, M., et al. (2018). Antioxidant potential of herbal preparations and components from *Galactites elegans* (All.) Nyman ex Soldano. *Evidence-Based Complementary and Alternative Medicine*, 2018, 9294358.
17. Parisi, V., Vassallo, A., Pisano, C., Signorino, G., Cardile, F., Sorrentino, M., et al. (2020). A herbal mixture from propolis, pomegranate, and grape pomace endowed with anti-inflammatory activity in an in vivo rheumatoid arthritis model. *Molecules*, 25(9), 2255.
18. Fazio, A., Iacopetta, D., La Torre, C., Ceramella, J., Muià, N., Catalano, A., et al. (2018). Finding solutions for agricultural wastes: Antioxidant and antitumor properties of pomegranate Akko peel extracts and β -glucan recovery. *Food & function*, 9(12), 6618-6631.
19. Grande, F., Parisi, O. I., Mordocco, R. A., Rocca, C., Puoci, F., Scrivano, L., et al. (2016). Quercetin derivatives as novel antihypertensive agents: Synthesis and physiological characterization. *European Journal of Pharmaceutical Sciences*, 82, 161-170.
20. Caruso, A., Ceramella, J., Iacopetta, D., Satumino, C., Mauro, M. V., Bruno, R., et al. (2019). Carbazole derivatives as antiviral agents: an overview. *Molecules*, 24(10), 1912.
21. Omran, Z., Bader, A., Porta, A., Vandamme, T., Anton, N., Alehaideb, Z., et al. (2020). Evaluation of Antimicrobial Activity of Triphala Constituents and Nanoformulation. *Evidence-Based Complementary and Alternative Medicine*, 2020, 6976973.
22. Vassallo, A., Armentano, M. F., Miglionico, R., Caddeo, C., Chirollo, C., Gualtieri, M. J., et al. (2020). Hura crepitans L. extract: Phytochemical characterization, antioxidant activity, and nanoformulation. *Pharmaceutics*, 12(6), 553.
23. Sinisgalli, C., Faraone, I., Vassallo, A., Caddeo, C., Bisaccia, F., Armentano, M. F., et al. (2020). Phytochemical profile of *Capsicum annum* L. cv Senise, incorporation into liposomes, and evaluation of cellular antioxidant activity. *Antioxidants*, 9(5), 428.
24. Satumino, C., Popolo, A., Ramunno, A., Adesso, S., Pecoraro, M., Plutino, M. R., et al. (2017). Anti-inflammatory, antioxidant and crystallographic studies of N-Palmitoyl-ethanol Amine (PEA) derivatives. *Molecules*, 22(4), 616.
25. Paesano, N., Marzocco, S., Vicidomini, C., Satumino, C., Autore, G., De Martino, G., Sbardella, G. (2005). Synthesis and biological evaluation of 3-benzyl-1-methyl- and 1-methyl-3-phenyl-isothioureas as potential inhibitors of iNOS. *Bioorganic & Medicinal Chemistry Letters*, 15(3), 539-543.
26. Vassallo, A., Vaccaro, M. C., De Tommasi, N., Dal Piaz, F., Leone, A. (2013). Identification of the plant compound geraniin as a novel Hsp90 inhibitor. *PLoS One*, 8(9), e74266.
27. Francomano, F., Caruso, A., Barbarossa, A., Fazio, A., La Torre, C., Ceramella, J., et al. (2019). β -Caryophyllene: a sesquiterpene with countless biological properties. *Applied Sciences*, 9(24), 5420.
28. Chimento, A., De Amicis, F., Sirianni, R., Sinicropi, M. S., Puoci, F., Casaburi, I., et al. (2019). Progress to improve oral bioavailability and beneficial effects of resveratrol. *International Journal of Molecular Sciences*, 20(6), 1381.
29. Vassallo, A., Capasso, A., Satumino, C. (2021) Phytotherapeutic strategy as a powerful approach for the prevention and therapy of Alzheimer's Disease. *Pharmacologyonline*, 2, 992-1019.

30. Santana-Rios, G., Orner, G. A., Amantana, A., Provost, C., Wu, S. Y., Dashwood, R. H. (2001). Potent antimutagenic activity of white tea in comparison with green tea in the Salmonella assay. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 495(1-2), 61-74.

31. Lambert, J. D., Elias, R. J. (2010). The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. *Archives of Biochemistry and Biophysics*, 501(1), 65-72.

32. Tsubono, Y., Nishino, Y., Komatsu, S., Hsieh, C. C., Kanemura, S., Tsuji, I., et al. (2001). Green tea and the risk of gastric cancer in Japan. *New England Journal of Medicine*, 344(9), 632-636.

33. Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., Corti, A. (2006). Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. *Cancer research*, 66(2), 1234-1240.

34. Xu, Y., Ho, C. T., Amin, S. G., Han, C., Chung, F. L. (1992). Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. *Cancer Research*, 52(14), 3875-3879.

35. Nie, J. Y., Zhao, Q. (2017). Beverage consumption and risk of ulcerative colitis: Systematic review and meta-analysis of epidemiological studies. *Medicine*, 96(49), e9070.

36. De Maio, A. C.; Basile, G.; Iacopetta, D., Catalano, A., Ceramella, J., Cafaro, D et al. The significant role of nutraceutical compounds in ulcerative colitis treatment. *Current Medicinal Chemistry*, 2021, accepted.

37. Strocchia, M., Terracciano, S., Chini, M. G., Vassallo, A., Vaccaro, M. C., Dal Piaz, F., et al. (2015). Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold. *Chemical Communications*, 51(18), 3850-3853.

38. Caddeo, C., Chessa, M., Vassallo, A., Pons, R., Diez-Sales, O., Fadda, A. M., Manconi, M. (2013). Extraction, purification and nanoformulation of natural phycoyanin (from Klamath algae) for dermal and deeper soft tissue delivery. *Journal of Biomedical Nanotechnology*, 9(11), 1929-1938.

39. Jung, Y. D., Kim, M. S., Shin, B. A., Chay, K. O., Ahn, B. W., Liu, W., et al. (2001). EGCG, a major

component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. *British Journal of Cancer*, 84(6), 844-850.

40. Liang, Y. C., Lin-shiau, S. Y., Chen, C. F., Lin, J. K. (1997). Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. *Journal of Cellular Biochemistry*, 67(1), 55-65.

41. Adachi, S., Shimizu, M., Shirakami, Y., Yamauchi, J., Natsume, H., Matsushima-Nishiwaki, R., et al. (2009). (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. *Carcinogenesis*, 30(9), 1544-1552.

42. Adachi, S., Nagao, T., To, S., Joe, A. K., Shimizu, M., Matsushima-Nishiwaki, R., et al. (2008). (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. *Carcinogenesis*, 29(10), 1986-1993.

43. Adachi, S., Nagao, T., Ingolfsson, H. I., Maxfield, F. R., Andersen, O. S., Kopelovich, L., Weinstein, I. B. (2007). The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. *Cancer research*, 67(13), 6493-6501.

44. Ahn, H. Y., Hadizadeh, K. R., Seul, C., Yun, Y. P., Vetter, H., Sachinidis, A. (1999). Epigallocatechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). *Molecular biology of the cell*, 10(4), 1093-1104.

45. Min, K. J., Kwon, T. K. (2014). Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. *Integrative Medicine Research*, 3(1), 16-24.

46. Roy, A. M., Baliga, M. S., Katiyar, S. K. (2005). Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. *Molecular Cancer Therapeutics*, 4(1), 81-90.

47. Hastak, K., Gupta, S., Ahmad, N., Agarwal, M. K., Agarwal, M. L., Mukhtar, H. (2003). Role of p53 and NF- κ B in epigallocatechin-3-gallate-induced

- apoptosis of LNCaP cells. *Oncogene*, 22(31), 4851-4859.
48. Catalano, A., Iacopetta, D., Pellegrino, M., Aquaro, S., Franchini, C., Sinicropi, M. S. (2021). Diarylureas: Repositioning from antitumor to antimicrobials or multi-target agents against new pandemics. *Antibiotics*, 10(1), 92.
49. Catalano, A., Iacopetta, D., Sinicropi, M. S., Franchini, C. (2021). Diarylureas as antitumor agents. *Applied Sciences*, 11(1), 374.
50. Catalano, A., Sinicropi, M. S., Iacopetta, D., Ceramella, J., Mariconda, A., Rosano, C., et al. (2021). A review on the advancements in the field of metal complexes with Schiff bases as antiproliferative agents. *Applied Sciences*, 11(13), 6027.
51. Terracciano, S., Russo, A., Chini, M. G., Vaccaro, M. C., Potenza, M., Vassallo, A., et al. (2018). Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain. *Scientific reports*, 8(1), 1-11.
52. Cioffi, G., Dal Piaz, F., Vassallo, A., Venturella, F., De Caprariis, P., De Simone, F., De Tommasi, N. (2008). Antiproliferative oleanane saponins from *Meryta denhamii*. *Journal of natural products*, 71(6), 1000-1004.
53. Vassallo, A., Bonomo, M. G., Finelli, F., Salzano, G., Catalano, A., Sinicropi, M. S., Capasso, A., Satumino, C. (2021) Chemopreventive molecules of coffee and beneficial metabolic effects. *Pharmacologyonline*, 2, 249-257.
54. Caputo, M., De Rosa, M. C., Rescigno, T., Zirpoli, H., Vassallo, A., De Tommasi, N., et al. (2014). Binding of polyunsaturated fatty acids to LXRA and modulation of SREBP-1 interaction with a specific SCD1 promoter element. *Cell Biochemistry and Function*, 32(8), 637-646.
55. Iacopetta, D., Ceramella, J., Catalano, A., Satumino, C., Bonomo, M. G., Franchini, C., Sinicropi, M. S. (2021). Schiff Bases: Interesting Scaffolds with Promising Antitumoral Properties. *Applied Sciences*, 11(4), 1877.
56. Vassallo, A., De Tommasi, N., Merfort, I., Sanogo, R., Severino, L., Pelin, M., et al. (2013). Steroids with anti-inflammatory activity from *Vernonia nigritiana* Oliv. & Hiern. *Phytochemistry*, 96, 288-298.
57. Vassallo, A., Santoro, V., Pappalardo, I., Santarsiero, A., Convertini, P., De Luca, M., et al. (2020). Liposome-mediated inhibition of inflammation by hydroxycitrate. *Nanomaterials*, 10(10), 2080.
58. Chen, H., Yao, K., Chang, X., Shim, J. H., Kim, H. G., Malakhova, M., et al. (2015). Computational and biochemical discovery of RSK2 as a novel target for epigallocatechin gallate (EGCG). *PLoS One*, 10(6), e0130049.
59. Cho, Y. Y., Yao, K., Bode, A. M., Bergen, H. R., Madden, B. J., Oh, S. M., et al. (2007). RSK2 mediates muscle cell differentiation through regulation of NFAT3. *Journal of Biological Chemistry*, 282(11), 8380-8392.
60. Sassone-Corsi, P., Mizzen, C. A., Cheung, P., Crosio, C., Monaco, L., Jacquot, S., et al. (1999). Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. *Science*, 285(5429), 886-891.
61. Dal Piaz, F., Vassallo, A., Rubio, O. C., Castellano, S., Sbardella, G., De Tommasi, N. (2011). Chemical biology of histone acetyltransferase natural compounds modulators. *Molecular Diversity*, 15(2), 401-416.
62. Cho, Y. Y., Yao, K., Kim, H. G., Kang, B. S., Zheng, D., Bode, A. M., Dong, Z. (2007). Ribosomal S6 kinase 2 is a key regulator in tumor promoter-induced cell transformation. *Cancer Research*, 67(17), 8104-8112.
63. Derewenda, U., Artamonov, M., Szukalska, G., Utepbergenov, D., Olekhovich, N., Parikh, H. I., et al. (2013). Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution. *Acta Crystallographica Section D: Biological Crystallography*, 69(2), 266-275.
64. Utepbergenov, D., Derewenda, U., Olekhovich, N., Szukalska, G., Banerjee, B., Hilinski, M. K., et al. (2012). Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. *Biochemistry*, 51(33), 6499-6510.
65. Das, S., Tanwar, J., Hameed, S., Fatima, Z., Manesar, G. (2014). Antimicrobial potential of epigallocatechin-3-gallate (EGCG): a green tea polyphenol. *Journal of Biochemical and Pharmacological Research*, 2(3), 167-74.
66. Ishwariya, D. B., Babu, D. N. A., Masthan, D. K., Anitha, D. N. (2020). Treatment options for Oral Potentially Malignant Disorder (OPMDs). *European*

- Journal of Molecular & Clinical Medicine*, 7(3), 1832-1843.
67. Iacopetta, D., Carocci, A., Sinicropi, M. S., Catalano, A., Lentini, G., Ceramella, J., et al. (2017). Old drug scaffold, new activity: thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression. *ChemMedChem*, 12(5), 381-389.
68. Lai, Y. H., Sun, C. P., Huang, H. C., Chen, J. C., Liu, H. K., Huang, C. (2018). Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice. *BMC Complementary and Alternative Medicine*, 18(1), 1-7.
69. Wang, Y. Q., Li, Q. S., Zheng, X. Q., Lu, J. L., Liang, Y. R. (2021). Antiviral effects of green tea egcg and its potential application against COVID-19. *Molecules*, 26(13), 3962.
70. Catalano, A. (2020). COVID-19: Could Irisin Become the Handyman Myokine of the 21st Century. *Coronaviruses*, 1(1), 32-41.
71. Steinmann, J., Buer, J., Pietschmann, T., Steinmann, E. (2013). Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. *British Journal of Pharmacology*, 168(5), 1059-1073.
72. Rosato, A., Catalano, A., Carocci, A., Carrieri, A., Carone, A., Caggiano, G., et al. (2016). In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of *Candida* spp. *Bioorganic & Medicinal Chemistry*, 24(5), 1002-1005.
73. Hengge, R. (2019). Targeting bacterial biofilms by the green tea polyphenol EGCG. *Molecules*, 24(13), 2403.
74. Pozzi, C., Ferrari, S., Cortesi, D., Luciani, R., Stroud, R. M., Catalano, A., et al. (2012). The structure of *Enterococcus faecalis* thymidylate synthase provides clues about folate bacterial metabolism. *Acta Crystallographica Section D: Biological Crystallography*, 68(9), 1232-1241.
75. Singla, R. K., Dubey, A. K. (2019). Molecules and Metabolites from Natural Products as Inhibitors of Biofilm in *Candida* spp. pathogens. *Current Topics in Medicinal Chemistry*, 19(28), 2567.
76. Weinreb, O., Amit, T., Mandel, S., Youdim, M. B. (2009). Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neurotogenic properties. *Genes & Nutrition*, 4(4), 283-296.
77. Lopez, T. E., Pham, H. M., Nguyen, B. V., Tahmasian, Y., Ramsden, S., Coskun, V., et al. (2016). Green tea polyphenols require the mitochondrial iron transporter, mitoferrin, for lifespan extension in *Drosophila melanogaster*. *Archives of Insect Biochemistry and Physiology*, 93(4), 210-221.
78. Carrisi, C., Madeo, M., Morciano, P., Dolce, V., Cenci, G., Cappello, A. R., et al. (2008). Identification of the *Drosophila melanogaster* mitochondrial citrate carrier: bacterial expression, reconstitution, functional characterization and developmental distribution. *Journal of Biochemistry*, 144(3), 389-392.
79. Iacopetta, D., Carrisi, C., De Filippis, G., Calcagnile, V. M., Cappello, A. R., Chimento, A., et al. (2010). The biochemical properties of the mitochondrial thiamine pyrophosphate carrier from *Drosophila melanogaster*. *The FEBS journal*, 277(5), 1172-1181.




Figure 1. Structure of epigallocatechin-3-gallate (EGCG).




Figure 2. Structure of epigallocatechin (EGC).




Figure 3. Structure of epicatechin-3-gallate (ECG)




Figure 4. Structure of epicatechin (EC).